Section 1: Introduction 1.1- Early development of bioresorbable scaffold Section 2: Principles of bioresorption, vascular application 2.1- Degradable, biodegradable and bioresorbable polymers for time-limited therapy 2.2- Lactic acid-based polymers in depth 2.3- Scaffold processing 2.4- Basics of biodegradation of magnesium 2.5- Basics of biodegradation of iron scaffold Section 3: From bench test to preclinical assessment 3.1- Unlocking scaffold mechanical properties 3.

2- Bench testing for polymeric bioresorbable scaffolds 3.3- Bench test for magnesium scaffold 3.4- Simulation of flow and shear stress 3.5- Preclinical assessment of bioresorbable scaffolds and regulatory implication Section 4: Lesson learned from preclinical assessment 4.1- PLA scaffold 4.2- Iron Section 5: Imaging to evaluate the bioresorbable scaffold: A corelab perspective, methodology of measurement and assessment 5.1- Quantative coronary angiography of bioresorbable vascular scaffold: a corelab perspective 5.2- Assessment of bioresorbable scaffolds by IVUS: echogenicity, virtual histology and palpography 5.

3- Optical coherence tomography analysis vascular scaffold in comparison with metallic stents: a corelab perspective 5.4- Non-invasive coronary tomography analysis after bioresorbable scaffold implantation 5.5- Angiography is sufficient 5.6- Intravascular ultrasound is a must in bioresorbable scaffold implantation 5.7- OCT is the way to go 5.8- Imaging to evaluate the bioresorbable scaffold. Clinician''s perspective: I need both (IVUS and OCT) 5.9- Multislice computed tomography as a modality of follow-up Section 6: Clinical evidence of randomised and non-randomised trials: personal perspective 6.

1- What are appropriate clinical endpoints? From device failure assessment to angina evaluation 6.2- Angina reduction after BRS implantation: correlation with changes in coronary haemodynamics 6.3- Comparison of everolimus eluting bioresorbable scaffolds with everolimus eluting metallic stents for treatment of coronary artery stenosis: Three-year follow-up of the Absorb II randomized trial 6.4- The ABSORB China trial 6.5- ABSORB Japan 6.6- What have we learned from meta-analysis of 1 year outcomes with the Absorb bioresorbable scaffold in patients with coronary heart disease 6.7- Summary of investigator-driven registries on absorb bioresorbable vascular scaffolds 6.8- Investigator-driven randomised trials 6.

9- The DESolve scaffold 6.10- Results of clinical trials with BIOTRONIK magnesium scaffolds 6.11- The REVA medical program: from ReZolve (R) to Fantom (R) 6.12- The Amaranth''s bioresorbable vascular scaffold technology 6.13- The mirage microfiber sirolimus eluting coronary scaffold 6.14- The Igaki-Tamai stent: the legacy of the work of Hideo Tamai Section 7: Clinical evidence in specific patient subsets: personal perspective 7.1- Left main interventions with BRS 7.2- Bioresorbable scaffolds in bifurcations 7.

3- BVS in chronic total occlusions: clinical evidence, tips and tricks 7.4- Bioresorbable scaffolds in diffuse disease 7.5- Bioresorbable scaffolds in mulitvessel coronary disease 7.6- Bioresorbable coronary scaffolds in non-St elevation acute coronary syndromes 7.7- Bioresorbable vascular scaffold in ST-segment elevation myocardial infarction: clinical evidence, tips and tricks 7.8- Bioresorbable scaffolds for treating coronary artery disease in patients with diabetes mellitus 7.9- BRS in calcified lesions 7.10- BRS textbook: invasive sealing of vulnerable, high-risk lesions Section 8: Complications (incidence, diagnosis, potential mechanisms and treatment) 8.

1- Acute and subacute scaffold thrombosis 8.2- Late and very late scaffold thrombosis 8.3- Treatment of bioresorbable scaffold failure 8.4- Recoil and bioresorbable scaffolds 8.5- Scaffold disruption and late discontinuities 8.6- The incidence, potential mechanism of side-branch occlusion after implantation of bioresorbable scaffold(s): insights from ABSORB II Section 9: Tips and tricks to implant BRS 9.1- Tips and tricks for implanting BRS: sizing, pre- and post-dilatation 9.2- Approach to bifurcation lesions Section 10: Emerging technologies (pre-CE mark, pre-FA, pre-PMDA and pre-CFDA) 10.

1- Overview of the field 10.2- MeRes100 (TM)- a sirolimus eluting bioresorbable vascular scaffold system 10.3- XINSORB bioresorbable vascular scaffold 10.4- NeoVas (TM) bioresorbable coronary scaffold system 10.5- ArterioSorb (TM) bioresorbable scaffold by Arterius Ltd 10.6- Lifetech 10.7- Abbott: new generation absorb scaffold.